The EBMT Trainee Committee
Trainee Pearls
Welcome to “Trainee Pearls”, a new initiative brought to you by the EBMT Trainee Committee to deliver the most important messages (“the pearls”) of high-profile research works in hematology and bone marrow transplant to our fellow trainees all over the world. The topics will span from classical hematology to more focused bone marrow transplant research. The selected research article will be discussed directly with young authors who have been involved with the published work.
N'hésitez pas à visiter le site du podcast et à soutenir son créateur : podcasters.spotify.com
Auteur
The EBMT Trainee Committee
Catégorie
Site du podcast
Dernier épisode
29 oct. 2023
Où écouter ?
Les podcasts dans l'appli Replaio Radio Bientôt disponibleLes podcasts arrivent très bientôt dans l'appli. Installe-la dès maintenant et découvre en avant-première une toute nouvelle façon de vivre les podcasts
Épisodes
#18 Jurjen Versluis: Transplant for high-risk MDS 29.10.2023 20:34
Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study. https://pubmed.ncbi.nlm.nih.gov/37607457/ ALSO AS VIDEO ON https://youtu.be/JbHS_-2sJQc CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://w...
#17 Nathanial Anderson: Signatures and persistence of CAR-T cells 05.09.2023 23:02
In this study, Nathanial and colleagues systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. Article: https://www.nature.com/articles/s41591-023-02415-3 As VIDEO on https://youtu.be...
#16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma 14.07.2023 17:17
Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. Aina and colleagues assessed the safety and activity of ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma. https://...
#15 Francesca del Bufalo: CAR-T cells for neuroblastoma 20.05.2023 23:54
Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. In an academic, phase 1–2 clinical trial, the investigators enrolled patients (1 to 25 years of age) with relapsed or refractory, high-risk neuroblastoma in order to test autologous, third-genera...
#12 Justin Loke: Cytogenetics and TP53 in BMT for AML 05.12.2022 14:55
The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort. Article: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr....
#11 Ferran Nadeu: Early seeding of Richter transformation 22.09.2022 25:51
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. Article: https://www.nature.com/articles/s41591-022-01927-8 ALSO AS AUDIO ON https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132 ...
#10 Elsa Bernard: IPSS-M in MDS 23.08.2022 28:33
Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are not yet used in the risk stratification of patients with MDS. Combining genomic profiling with hematologic and cytogenetic parameters, the I...
#9 Alice Bertaina: Stem cell-kidney transplant for SIOD 07.07.2022 27:41
Schimke immuno-osseous dysplasia (SIOD) is a multisystem disorder that is inherited in an autosomal recessive pattern. It usually manifests first with growth failure. Other features of the disease are generally noted in the ensuing evaluation of the growth failure or develop in the following years. Article: https://www.nejm.org/doi/10.1056/NEJMoa2117028?u...
#8 Marie Passet: Novel high-risk B-cell ALL 08.06.2022 25:24
Oncogenic alterations underlying B-cell acute lymphoblastic leukemia (B-ALL) in adults remain incompletely elucidated. To uncover novel oncogenic drivers, Marie and her team performed RNA-seq and whole-genome analyses in a large cohort of unresolved B-ALL. Marie and colleagues identified a novel subtype characterized by a distinct gene expression signature and the uni...
#7 Rafal Machowicz: Transplant for HLH 28.04.2022 36:09
Hemophagocytic lymphohistiocytosis (HLH; hemophagocytic syndrome) is a rare syndrome of potentially fatal, uncontrolled hyperinflammation. Allogeneic hematopoietic stem cell transplantation is indicated in primary, recurrent or progressive HLH, but information about its outcomes in the adult population is limited. Rafal works at the Department of Hematology, Transplantation...
#6 Madelon de Jong: Myeloma & tumor microenvironment 10.03.2022 25:47
Progression and persistence of malignancies are influenced by the local tumor microenvironment, and future eradication of currently incurable tumors will, in part, hinge on our understanding of malignant cell biology in the context of their nourishing surroundings. Article: https://www.nature.com/articles/s41590-021-00931-3 CONNECT with Trainee Committee https://twitt...
#5 Oscar Brück: Machine learning in histopathology 04.02.2022 32:32
Histopathology is elementary in the diagnostics of patients with MDS, but its high-dimensional data are underused. By elucidating the association of morphologic features with clinical variables and molecular genetics, this study highlights the vast potential of convolutional neural networks in understanding MDS pathology and how genetics is reflected in BM morphology....
#4 Christopher Gibson: Clonal Hematopoiesis and transplantation 21.01.2022 40:01
Clonal hematopoiesis (CH) is an age-related, asymptomatic condition in which leukemia-associated somatic mutations are detected in the blood of individuals without a hematologic malignancy. In the nontransplant setting, CH is uniformly associated with adverse outcomes, including an elevated risk of developing hematologic malignancies and an increased risk of nonhemato...
#3 Francesca Tucci: Hurler Syndrome and gene therapy 08.01.2022 28:07
Hurler syndrome, also known as mucopolysaccharidosis Type IH (MPS-IH), Hurler's disease, and formerly gargoylism, is a genetic disorder that results in the buildup of large sugar molecules called glycosaminoglycans (GAGs) in lysosomes. The inability to break down these molecules results in a wide variety of symptoms caused by damage to several different organ systems,...
#2 Emma Groarke: VEXAS syndrome 05.12.2021 30:50
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described autoinflammatory syndrome characterized by diffuse inflammatory manifestations, predisposition to hematological malignancy, and an association with a high rate of thrombosis. VEXAS is attributed to somatic mutations in the UBA1 gene in hematopoietic stem and progenitor cells with myeloid restriction i...
#1 Sushree Sahoo: SAMD9/SAMD9L syndromes 22.11.2021 26:56
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Sahoo SS , et al. Nat Med. 2021 Oct;27(10):1806-1817. doi: 10.1038/s41591-021-01511-6
Podcasts similaires
Replaio n'est pas éditeur de podcasts ; les noms des émissions, les visuels et l'audio appartiennent à leurs auteurs et sont diffusés via des flux RSS publics